StemCell Therapy

Home Academics College of Science and Mathematics Biology Department Graduate Programs Biotechnology, MS

Degree Requirements | Admission Requirements | Transfer Credit Policy | Costs and Financial Aid

This MS program in biotechnology and biomedical science trains students in the theory and laboratory techniques used in biotechnology and biomedical science-two high technology areas of expanding national and local importance. The program provides a firm foundation in the principles underlying modern biotechnology techniques, and integrates this theoretical understanding with intensive training in a variety of laboratory skills and in computer applications to biotechnology.

The curriculum of the program consists of required courses in biology and biophysics, a required two-semester research experimentation course, and elective courses in biology, chemistry, and physics. Work in these courses is particularly appropriate for students with interests in the emerging fields of biotechnology, molecular genetics, tissue culture, and computerized laboratory technology.

Thirty credits are required for the master of science degree in biotechnology and biomedical science.

Each degree candidate is assigned to a three-member advising committee, which will be responsible for insuring that the student fulfills all requirements of the program and the Office of Graduate Studies.

All students must complete the following courses for a total of 9 credits:

All students must complete at least four of the following courses for a minimum of 12 credits:

Students must complete the remainder of credits (9 credits) by taking elective courses chosen from the following list. At least two must be biology courses.

Students wishing to substitute any other courses for those on this list of electives must have prior approval from their Academic Advising Committee and the graduate program director in biology.

Each student prepares a written report on his or her research work and must also take an oral examination, which will not necessarily be limited to the topic of the report. The student must submit an outline of the report to his or her advising committee before taking the oral examination.

Students may choose either an internship option or a thesis option, which will enable them to pursue a thesis research project in the laboratory of a faculty member. Thesis students have the option of taking 4 additional research credits, as Biol 699. This, in combination with two semesters of Biol 696, will allow for a maximum of 10 credits toward research.

Note: These degree requirements are subject to change as developments in the field affect the program's curriculum. Please contact the director of graduate programs in biology for the most current information.

Test of English as a Foreign Language (TOEFL official test score) is required for international applicants. For more information regarding minimal TOEFL scores go to Graduate Admissions. The stated interests of a prospective student must coincide to an acceptable degree with the faculty specialties represented in the program. The Biology Graduate Committee in conjunction with the Director of Graduate Programs in Biology is responsible for reviewing applications and for recommending candidates to the dean of graduate studies.

Applicants who have completed appropriate graduate course work at other accredited institutions may transfer the equivalent of six credits toward UMass Boston graduate degree requirements from courses in which the applicant received a grade of B or higher, provided these are courses that have not been used to fulfill requirements for another degree,andwere completed no more than seven years before the applicant's matriculation of UMass Boston.Transfer credit is subject to the final approval of the graduate program director and the dean of graduate studies.

As a public university, the costs of attending UMass Boston are moderate, especially for students who qualify as residents of Massachusetts. Financial aid is available in the form of grants, loans, and a limited number of assistantships that provide a stipend and remission of tuition.

For information about financial assistance please see the graduate assistance page, or write or call:

Office of Financial Aid Services University of Massachusetts Boston 100 Morrissey Blvd. Boston, MA 02125 617.287.6300

Please consult the frequently asked questions (FAQs) at the bottom of the preceding Graduate Programs home page.

Faculty in the School for the Environment and Computer Science and Chemistry Departments also participate in this program.

Please note: All information on this website is subject to change. This website is neither a contract nor an offer to make a contract.

See the article here:
Biotechnology, MS - University of Massachusetts Boston

The Bachelor of Science in Biotechnology program trains students in many disciplines including genetics, biochemistry and molecular biology and prepares them for entry into health sciences and analytical / research laboratories. Graduates possess the skills to perform laboratory tests using standardized laboratory procedures.

Graduates of the program will have completed the prerequisites necessary to be successful in graduate programs in the sciences. However, a Bachelor of Science in Biotechnology can also be a terminal program for individuals who wish to work in laboratory settings and other occupations.

The following objectives are designed to meet Keiser Universitys mission and its objectives.

To receive a Bachelor of Science in Biotechnology, students must earn 129 credit hours. Program requirements are as follows:

Lower Division General Education Courses( 31.0 credit hours )

Note: To view the PDF file linked above you will need to have Adobe Reader. To download a free copy of this software click here or go to the Adobe website at http://www.adobe.com.

See the rest here:
Biotechnology, BS - Keiser University

They employ biochemical, moleculobiological; and genetic methods alongside methods of engineering. The tasks of biotechnologists include the utilization of cell culture techniques, the operation of bioreactors, and the development of biotechnological procedures. They moreover convert methods developed in the laboratory into full-scale engineering operations, take full responsibility for the smooth running of production processes, or conceptualize and supervise bioprocess engineering systems Structure 1st 3rd semester: Core curriculum 4th semester: Master thesis and final exams Time model Full-time Academic year Winter semester: October January Summer semester: March June Contents Biotechnology (47%) Current Industrial Projects (12,5%) Scientific Methods & Master Thesis (33%) General Management (7,5%) Admission requirements Graduates of relevant Bachelor programs Graduates of post secondary courses pertaining to the intended studies (i.e. process engineering, chemical engineering, biological engineering, biotechnology) Selection process Career background (30%) Written exam (20%) Interview (50%) Application Online. Please consider the indicated deadlines Contact MCI MANAGEMENT CENTER INNSBRUCK The Entrepreneurial School Biotechnology Maximilianstrae 2 A-6020 Innsbruck/Austria +43 512 2070-3800, This email address is being protected from spambots. You need JavaScript enabled to view it.

See the original post here:
Biotechnology - MCI Management Center Innsbruck

The work of the Biology and Biotechnology Department at WPI goes far beyond the theoretical. Students, faculty, and industry collaborate in research and discovery to solve problems that affect us all. Their goals: to help treat and cure common, dread diseases, like Alzheimers and cancer; heal wounds faster; create a greener world through science; and use computer science techniques to solve flesh-and-blood problems.

And weve only scratched the surface of what the Biology and Biotechnology Department is doing. Its state-of-the-art new research center, the Life Sciences and Bioengineering Center at Gateway Park, is practically bursting at the seams with fundamental and applied research, conducted with cutting-edge instrumentation and tools. Here, graduate and select undergraduate students work across disciplines and with companies in the field.

Graduates of the Biology and Biotechnology Department at WPI go on to myriad careers in industry and academia, across organizations large and small. And the research interests of our faculty encompass a similarly large range.

Its an exciting time for the life sciences. We invite you to learn more about how the Biology and Biotechnology Department can help you reach your educational and career goals.

Assistant Professor Luis Vidali describes his collaboration with Assistant Professor Erkan Tuzel of the Department of Physics to investigate cell biology and help develop a more active biophysics program at WPI.

Follow this link:
Biology & Biotechnology - WPI

STATEMENT OF INTEREST OF AMICUS CURIAE

The Biotechnology Industry Organization (BIO) is the world's largest biotechnology trade association, providing advocacy, development, and communications services for over 1,100 members worldwide. BIO members - many of whom are small, emerging companies-involved in the research and development of innovative healthcare, agricultural, industrial, and environmental biotechnology products.

BIO has no direct stake in the result of this appeal, nor does BIO take a position on the ultimate validity or infringement of the claims to a method of obtaining viable hepatocytes for medical uses. No counsel for a party authored this brief in whole or in part, and no such counsel or party, nor any person other than the amicus curiae or its counsel, made a monetary contribution intended to fund the preparation or submission of this brief. This brief is solely the work of BIO and its counsel and reflects BIO's consensus view, but not necessarily the view of any individual member or client. BIO and its members are concerned that the development and commercialization of a diverse array of biotechnologies, including diagnostic testing and personalized medicine, will be hampered, if not precluded, if this Court does not address the mounting uncertainty currently afflicting patentable subject matter jurisprudence.

Unfortunately, the District Courts decision has done nothing to alleviate that uncertainty, but instead has exacerbated doubts as to whether meaningful patent protection remains available in the United States for many biotechnology inventions, and if so, the extent of that protection and the means to draft commercially meaningful method claims that meet the newly heightened standard for patent eligibility. The invention in this case would traditionally have been deemed eligible subject matter for patenting under 35 U.S.C. 101. It provides an excellent opportunity for the court to provide timely clarification on issues of critical concern to BIO and its members.

Excerpt from:
Brief of the Biotechnology Industry Organization as Amicus ...

Federal Activities Report on the Bioeconomy page cover

5/4/2016 UPDATE:

Bioeconomy Webinar Information: Thursday, May 5, 2 p.m.4 p.m. Eastern Time Session Link: https://thinktank.inl.gov/login.html?sessionID=59 Session Passkey: 123 Call in: +1 (562) 247-8422 Access Code: 287-084-886

The USDA and other federal agencies recently released the Federal Activities Report on the Bioeconomy (FARB) documenting federal agency activities aimed at helping to develop and support the bioeconomy an emergingpart of the overall U.S. economy. Emphasis is specifically placed on the production and use of biofuels, bioproducts, and biopower. USDA Chief Scientist and Under Secretary for Research, Education, and Economics (REE), Dr. Catherine Woteki, stresses these fuels, power, and products are produced using biomassagricultural residues, grasses, energy crops, forestry trimmings, algae, and other sourcesinstead of fossil fuels.

The report also delves into the Billion Ton Bioeconomy Vision, an effort coordinated through the Biomass Research and Development (R&D) Board. Comprised of industry experts from the Departments of Energy (DOE), Agriculture (USDA), Interior (DOI), Transportation (DOT), Defense (DoD), and the Environmental Protection Agency (EPA), the National Science Foundation (NSF), and the Office of Science and Technology Policy (OSTP), the Board is committed to collaboration among federal agencies on bioeconomy conceptions working to triple the size of todays bioeconomy by 2030to more than a billion tons of biomass. Read more

Tags: bioeconomy, biofuels, Biomass, BioPreferred, Biotechnology, California, Department of Defense, Department of Energy, Department of Interior, Department of Transportation, Dr. Catherine Woteki, Harry Baumes, National Science Foundation, OCE, REE, U.S. Environmental Protection Agency, White House

Economic Growth, Energy

Innovation, biotechnology and big data are changing the way we produce, distribute and even consume food. From using innovative approaches to improve food safety to sharing market data to assist producers in reaching larger markets, big data and new technologies continue to change the face of agriculture. USDA strives to meet these evolving challenges and will be discussing these issues through the lens of agriculture at the 2015 Agricultural Outlook Forum on Feb. 19-20 in Arlington, Virginia.

Big data isnt just massive amounts of numbers and codes for scientists, researchers and marketers. That information, when interpreted and applied, can help people understand and change the world around them. We are discussing how data helps producers of agricultural commodities in adapting their strategies to meet changing consumer demands, marketing practices and technologies. Read more

Organic meat and poultry producers can now use a streamlined process to get approval for labels verifying that their products do not include genetically engineered (GE) ingredients.

USDAs Food Safety and Inspection Service (FSIS) released new procedures for including a non-genetically engineered statement on the label of organic meat and poultry products. This is consistent with organic regulations, which have always prohibited the use of GE in all organic products. Now, with the new process, it will be easier for certified organic entities to add these claims to existing FSIS-approved products, speeding up the label review process. Read more

Tags: AMS, Biotechnology, Farmers, Food Safety, FSIS, genetic engineering, GMO, Meat and Poultry, National Organic Program, NOP, NRCS, organic, Organic 101, organic certification, Poultry, Tom Vilsack

Food Safety

Emmanuel Amoakwah, a Borlaug Fellow from Ghana currently studying at Ohio State University, gives a presentation on climate change during the Borlaug Symposium at the 2013 World Food Prize on Oct. 16. Approximately 40 Borlaug Fellows and their mentors attended the annual event in Des Moines to network, meet members of the Borlaug family and high-level agricultural officials and this years World Food Prize Laureates. (Photo by Jared Henderson, University of Missouri)

Every year the World Food Prize recognizes the achievements of individuals who have advanced human development by improving the quality, quantity or availability of food in the world. Nobel Peace Prize Laureate Dr. Norman E. Borlaug created the prize, which emphasizes the importance of a nutritious and sustainable food supply for all people.

This years event was held from Oct. 16-19 in Des Moines, Iowa, and also included a USDA-sponsored symposium for 40 foreign scientists from 23 countries (and their university mentors) in the Foreign Agricultural Service Borlaug Fellowship Program. Since 2004, the program has provided U.S.-based training and collaborative research opportunity for scientists and policymakers from developing and middle-income countries to promote food security and economic growth. Read more

Tags: Biotechnology, Borlaug Fellowship Program, Climate Change, coffee, Economic Growth, FAS, food insecurity, Food Security, Iowa, Kenya, Norman Borlaug, Science, Tennessee, World Food Prize

Food and Nutrition, Food Security

Sec. Tom Vilsack visited the grain grading laboratory of GIPSA's Board of Appeals and Review (BAR) and the Grading Service Laboratory (GSL) on October 23, 2013. BAR staff explain their grading review process while BAR Chairman Jim Whalen looks on.

The Grain Inspection, Packers and Stockyards Administrations (GIPSA) National Grain Center (NGC) was proud to host Agriculture Secretary Tom Vilsack on Wednesday, October 23. The NGC, located in Kansas City, MO, is home to the Federal Grain Inspection Services (FGIS) Technology and Science Division along with staff from FGIS Quality Assurance and Compliance Division and Field Management Division.

The grain inspectors, scientists and engineers at the NGC provide a broad spectrum of grain inspection services and support within recently renovated state of the art laboratories. During the visit, NGC staff demonstrated how they oversee, develop and approve methods and instruments used for grain inspection that ensure the consistent standard of measuring quality essential to grain marketing. Read more

On Friday, May 17, 2013, in Mexico City, Mexico USDA Secretary Tom Vilsack led U.S. and Mexican agribusiness representatives in a discussion of priority issues affecting North American agriculture. The roundtables participants represented the breadth and diversity of agricultural trade between the United States and Mexico. Representatives from Grupo Bimbo, Gruma, Driscolls, Cargill, and others joined the Secretary, U.S. Ambassador to Mexico Anthony Wayne, and Acting Deputy Under Secretaries Suzanne Heinen and Max Holtzman to share their views on the opportunities and obstacles facing increased agricultural trade between the United States and Mexico. Read more

Tags: Biotechnology, Climate Change, ethanol, Farm Bill, Food Farm and Jobs Bill, Food Safety, immigration, Mexico, Renewable Energy, Suzanne Heinen, Tom Vilsack

Climate Change, Trade

Original post:
USDA Blog Biotechnology

PROGRAM DESCRIPTION

The Master of Science in Biotechnology program in the College of Medicine will prepare students to function in the industrial biotechnology environment. This program is designed to give students broad knowledge and training in the scientific and practical aspects of biotechnology.

The Master of Science in Biotechnology program in the College of Medicine will prepare students to function in the industrial biotechnology environment. This program is designed to give students broad knowledge and training in the scientific and practical aspects of biotechnology.

It involves innovative, hands-on and multidisciplinary learning approaches to educate and train students in scientific aspects of biotechnology. The courses and research training required of all students in this program are designed to develop independent thinking, team work and communication skills, which are highly desirable in the biotechnology industry. Students will be provided an industrial perspective and an understanding of product development at the same time as they are trained in the biotechnology techniques required for such development.

The Master of Science in Biotechnology program consists of a minimum of 30 semester credit hours of graduate courses offeredby the Burnett School of Biomedical Sciences inthe College of Medicine that includes 21 credit hours minimum of required courses, 3 credits of restricted electives,and 6 credit hours of thesis research as detailed below.

What makes this program unique is the focus on practical training offered to graduate students through masters thesis research in molecular biotechnology to perform jobs in laboratory environment that require scientific talent.

Students must take the following courses plus at least two credit hours of graduate seminar.

MCB 5722C Methods in Biotechnology (4 credit hours) or BSC 6407C Laboratory Methods in Molecular Biology (3 credit hours)

BSC 6432 Structure-Function-Relationships of Biomedical Sciences I (5 credit hours)

BSC 6433 Structure-Function-Relationships of Biomedical Sciences II (5 credit hours)

BSC 6431 Practice of Biomedical Sciences (3 credit hours)

PCB 5527 Genetic Engineering and Biotechnology (3 credit hours) or one of the following: BSC 5418 Tissue Engineering (3 credit hours), MCB 6417C Microbial Metabolism (3 credit hours), PCB 5025 Molecular and Cellular Pharmacology (3 credit hours)

Students will participate in at least two graduate seminar courses thatwill prepare them for making professional presentations with emphasis in biotechnology. The courseswill involve participation of speakers from the biotechnology industry with emphasis on an industrial perspective on biotechnology applications and product development.

Students willselect three credit hours of restricted electives from the list below.

Students will take a minimum of six credits of thesis research (MCB 6971) to complete their research and submit their thesis specializing in biotechnology research. Students are expected to have an in-depth discussion with at least three faculty members before choosing alaboratory for thesis research.The student and the Thesis Adviser/Major Professor will jointly recommend an advisory committee comprised of at least three members. The committee composition must reflect expertise relevant to the students thesis research and must be approved by the Graduate Committee. Students switching to change the composition of the Thesis Advisory Committee must also obtain approval from the Graduate Committee.

The thesis proposal defense requirement should be met and passed successfully no later than the end of the summer of the first year in the program. Students will not be allowed to register for courses for the Fall semester of their second year until this requirement is fulfilled. The Thesis Proposal requirement includes: 1) a written 5-page thesis proposal; 2) a thesis proposal defense in front of the thesis committee; and 3) questions by the thesis committee to test the student's understanding of the basic concepts in the field and relevant applications. The student will be evaluated on performance in all three sections. Should the student fail, a second opportunity will be provided within 2 weeks of the first attempt. A second failure will result in dismissal from the program.

An oral thesis defense is required. The defense will be in the format of:

A 50-minute presentation of the thesis work, including a 5-minute introduction

A 10-minute free period for the general audience to ask questions

A 1-hour closed-door examination by the Thesis Advisory Committee and the program faculty present

The thesis should be of significant scope and depth such that the work has made advances in the area of biotechnology. The MS thesis research must generate sufficient quantity and quality data to support the submission of a minimum of one manuscript. Approval of the final thesis will require consent from the majority of the Program Faculty who choose to review the thesis, inclusive of the Thesis Advisory Committee. Faculty members with dissenting vote on the thesis must provide written justification. Scientific journal review criteria will be used as guidelines by the faculty to evaluate the final thesis for its appropriateness for publication in the target journal.

Students will be evaluated on the progress in thesis research by the thesis advisory committee for fall and spring. Two consecutive unsatisfactory evaluations will result in dismissal from the program.

Students must pass a comprehensive exam to qualify for the Master of Science degree.

Students must successfully pass an oral comprehensive examination to test the understanding of the basic concepts in the field and relevant applications. The Comprehensive Examination will be conducted during the thesis proposal defense.The exam will be administered by the thesis committee. Should the student fail this exam, a second opportunity will be provided within 2 weeks of the first attempt. A second failure will result in dismissal from theprogram.

For information on general UCF graduate admissions requirements that apply to all prospective students, please visit theAdmissions section of the Graduate Catalog.Applicants mustapply online. All requested materials must be submitted by the establisheddeadline.

In addition to thegeneral UCF graduateapplication requirements, applicants to this program must provide:

Personal interviews are helpful but not required. Applicants whodo not have a competitiveGPA or GRE may occasionally be accepted if there is other convincing evidence of potential for high achievement and success.

Applicants who hold a BS degree in unrelated fields are expected to have the equivalent of 16 semester hours of credit in the biotechnology/biological sciences including a course in general microbiology, biochemistry or molecular biology or cell biology, plus one year of organic chemistry, one year of physics, basic university mathematics and statistics, and laboratory skills equivalent to the minimum required of our own undergraduates. Minor deficiencies may be remedied after acceptance by enrollment at the first opportunity in an appropriate course.

-

-

-

-

-

-

Fellowships are awarded based on academic merit to highly qualified students. They are paid to students through the Office of Student Financial Assistance, based on instructions provided by the College of Graduate Studies. Fellowships are given to support a students graduate study and do not have a work obligation. For more information, see UCF Graduate Fellowships, whichincludes descriptions of university fellowshipsand what you should do to be considered for a fellowship.

Read more:
Biotechnology MS Degree - UCF Graduate Catalog 2016-2017

Prepare for a cutting-edge career with a bachelor's degree in biological sciences from Miami Dade College. South Florida is home to two major life sciences research hubs and more than 1,300 companies that are creating the future right now and have a high demand for skilled workers. This program responds to the needs of our regions employers.

A capstone internship with a prospective employer or private/public partner moves beyond the classroom, allowing you to put your skills to the test in the real world.

The biotechnology concentration of this bachelors program helps you build the knowledge and skills youll need to succeed in the life sciences. As a biotechnology student, youll learn about:

Continued growth in the biotechnology and medical research fields is expected to continue to drive growth in the life sciences industry, especially in the South Florida region, which is rapidly evolving into a hot spot for life sciences research. An education in biotechnology opens doors to careers in a variety of workplaces, including:

These four-year programs combine extensive academic studies with the real-world experience students need to pursue a career in their selected field.

Continue reading here:
Biotechnology - Miami Dade College

More On This Industry Summary News Leaders & Laggards Company Index Industry Browser Related Industries Diagnostic Substances Drug Delivery Drug Manufacturers - Major Drug Manufacturers - Other Drug Related Products Drugs - Generic Top Industries Auto Manufacturers - Major Biotechnology Business Software & Services Chemicals - Major Diversified Communication Equipment Conglomerates Diversified Computer Systems Diversified Investments Diversified Utilities Drug Manufacturers - Major Electric Utilities Food - Major Diversified Industrial Metals & Minerals Major Airlines Major Integrated Oil & Gas Money Center Banks Property & Casualty Insurance Semiconductor - Broad Line Telecom Services - Domestic Tobacco Products, Other Complete Industry List... In-depth Company Dossier Reports on over 7,500 publicly traded U.S. companies. Click here for your free report. Industry Market Summary Biotechnology Composite Value:918.9 Today's Change:-0.68% S&P 500: -0.29% Biotechnology News Stemline Therapeutics SL-401 Phase 2 BPDCN Data Delivered Via Oral Presentation at ASCO; High Response Rates Demonstrated Across All Lines As Enrollment Proceeds Sat 7:07 pm ET (GlobeNewswire) NEW YORK, June 04, 2016-- Stemline Therapeutics, Inc. announced today the oral presentation of positive clinical data from its ongoing SL-401 Phase 2 potentially pivotal clinical trial in blastic plasmacytoid ... TESARO Provides Pipeline Update at ASCO Investor Briefing - (GlobeNewswire) Data Presented at ASCO 2016 Builds upon Foundation of Abraxane Plus Gemcitabine as a First-Line Treatment in Patients with Metastatic Pancreatic Cancer - (Business Wire) More News on Biotechnology: Latest News, Industry Top Performers Intraday Price Performance % Change Market Cap More Top Intraday Price Performers... Market Capitalization % Change Market Cap SHIRE [SHP.L] -0.94% $2607.6 B AMGEN [AMGN.MX] -0.52% $2216.5 B GILEAD SCIENCES [GILD.MX] -0.62% $2134.9 B SUN PHARMACEUTICALS INDUSTRIES [SUNPHARMA.NS] -1.26% $1831.4 B AMGEN-T [4332.HK] 0.00% $505.0 B More Top Companies by Market Cap... More Top Performers: by Valuation, by Growth, by Financial Strength Industry Calendar Upcoming Events Date Co Event 06/05/16 EXEL Exelixis Inc Investor/Analyst Briefing to Review Cabozantinib Data at the American Society of Clinical Oncology (ASCO) Annual Meeting 06/06/16 ARIA ARIAD Pharmaceuticals Investor and Analyst Briefing and Webcast 06/11/16 AGIO Agios Pharmaceuticals Inc Conference Call to Discuss Data from PKR Activators AG-348 and AG-519 More Upcoming Events... Recent Events Date Co Event 06/03/16 BLUE bluebird bio, Inc. coverage initiated by Cantor Fitzgerald 06/03/16 OMER Omeros Corporation coverage initiated by Cantor Fitzgerald 06/03/16 ONCE Spark Therapeutics, Inc. coverage initiated by Cantor Fitzgerald More Recent Events... Locate Industry by Company Enter Symbol: AdChoices Industry Statistics Market Capitalization: 9,619B Price / Earnings: 165.8 Price / Book: 23.4 Net Profit Margin (mrq): 19.7% Price To Free Cash Flow (mrq): -290.2 Return on Equity: 15.4% Total Debt / Equity: 105.0 Dividend Yield: 2.0% View Industry Browser Community Spotlight Most Active Boards Board Popularity CTRX PGLAF NRPH Unusually Active Boards Board Variance CTRX NRPH PDLI RSS Feeds

Add headlines to your personalized My Yahoo Page ( About My Yahoo and RSS )

View post:
Biotechnology Overview: Industry Center - Yahoo Finance

Latest News Sunday, Jun 5, 2016 Stemline Therapeutics SL-401 Phase 2 BPDCN Data Delivered Via Oral Presentation at ASCO; High Response Rates Demonstrated Across All Lines As Enrollment Proceeds GlobeNewswire - Sat 7:07 pm ET TESARO Provides Pipeline Update at ASCO Investor Briefing GlobeNewswire - Sat 7:00 pm ET Data Presented at ASCO 2016 Builds upon Foundation of Abraxane Plus Gemcitabine as a First-Line Treatment in Patients with Metastatic Pancreatic Cancer Business Wire - Sat 5:32 pm ET Juno Therapeutics Investigational CAR T Cell Product Candidate JCAR015 Shows High Response Rates in Adults with B-cell ALL Business Wire - Sat 5:15 pm ET Saturday, Jun 4, 2016 Celldex Therapeutics CDX1401, CDX301 Combination Generates Potent NY-ESO-1 Immune Responses in Patients with Melanoma GlobeNewswire - Sat 2:02 pm ET Juno Therapeutics Defined Composition CD19 Product Candidates Demonstrate Encouraging Clinical Outcomes and Tolerability Business Wire - Sat 10:08 am ET Five Prime Therapeutics Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 Presented at 2016 ASCO Annual Meeting GlobeNewswire - Sat 9:24 am ET Encorafenib-based Regimens Provide Improved PFS and OS in Difficult-to-Treat BRAF-Mutant Colorectal Cancer Compared to Historical Benchmarks PR Newswire - Sat 9:00 am ET Array BioPharma, Pierre Fabre and Merck KGaA, Darmstadt, Germany Announce Phase 3 BEACON CRC Trial PR Newswire - Sat 9:00 am ET Aduro Biotech Presents Encouraging Anti-Tumor Response Data From Ongoing Phase 1b Study in Malignant Pleural Mesothelioma at ASCO GlobeNewswire - Sat 9:00 am ET Halozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic Pancreatic Cancer Patients Treated With PEGPH20 PR Newswire - Sat 9:00 am ET ARIAD Presents Data from Mutational Profiling in Crizotinib-Resistant Patients Treated with Investigational Medicine Brigatinib Showing Similar Response Rates in Patients with and without Secondary ALK Mutations Business Wire - Sat 7:35 am ET ARIAD Presents Long-Term Phase 1/2 Trial Follow up on Investigational Drug Brigatinib with Median Time on Treatment of 17 Months in ALK+ NSCLC Patients Business Wire - Sat 7:35 am ET INTREXON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Intrexon Corporation Business Wire - Fri 10:07 pm ET June is month to watch for more IPO news at bizjournals.com - Fri 8:47 pm ET [$$] Frazier, OrbiMed Join $100M Financing for Lion Biotechnologies at The Wall Street Journal Online - Fri 8:44 pm ET Celator Pharmaceuticals, Inc. Acquisition May Not Be in the Best Interests of CPXX Shareholders PR Newswire - Fri 6:21 pm ET SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in NewLink Genetics Corporation of Class Action Lawsuit and Upcoming Deadline - NLNK - Fri 6:10 pm ET SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Intrexon Corporation of Class Action Lawsuit and Upcoming Deadline - XON - Fri 5:58 pm ET Shire Closes Baxalta Buyout, Sparking Higher Growth Forecast at Investor's Business Daily, Inc. - Fri 5:32 pm ET More Latest News...

Read the rest here:
Biotechnology Industry News: Industry Center - Yahoo Finance

In extraordinary ways, today the research and developement in biotechnology is demonstrating the power of scientific ideas to change the world ! The future of biotechnology is not only good but it is great ! Why only future , the present of biotech is so bright that its development will further make it to shine more and more. Today biotechnology is inspiring new students to go ahead with their biotechnology knowledge on such platforms were sky is the limit. Biotechnology has a very strong and promising future. The simple reason for this is it covers the entire field of science and its applications. These includes but not limited to filed as medical, agricultural, engineering, computational, and industrial process all together are now using a integrated approach to improve product quality, efficiency, cost, and environmental sustainability. Nanotechnology, information technology are also helping biotechnology in various way to improve the standards of product and reduce the side effects, cycle time of production with safety measures of patients, society and environment.

With the help of Biotechnology new era is on the way to emerge with the self-directed evolutions. Mankind is on its way to develop self-engineered organism, biochemical pathways, rDNA, self-design proteins, genetically engineered vegetables for improved productivity and nutritional values. Now with the help of Biotechnology new thinking & implementation of biotechnology applications in physiology of body, gene alterations, protein study, and nanotechnology are being done. All this will help to curb all types of diseases; disorders will help to build the humanity with self-protected and controlled evolution.

The area of application of biotechnology is vast. Few examples it includes unique products development, today Monoclonal antibodies which are new tools to detect and localize specific biomolecules. The biotechnology had today developed such monoclonal anitbiotics which In principle, can be made against any macromolecule and used to specifically locate, purify or even potentially destroy molecule as for example with anticancer drugs.

Biotechnology is helping and is being worldwide utilized in solving crimes with DNA identifications. It also allows scientists and other to produce banks of DNA, RNA and proteins, while mapping the human genome. Tracers are used to synthesize specific DNA or RNA probes, which are very essential to specify sequences which is involved in genetic disorders.

With genetic engineering & biotechnology, new proteins are increasingly synthesized globally and used for variuos therapies. They can be introduced into other forms of life like plants or animal genomes, thus a new type of disease resistant plants are generated, capable of living in extreme unfavorable environments (i.e. temperature, Ph, Salt, Desert extremes,...). When introduced into bacteria, these proteins have also produced new antibiotics and useful therapeutic drugs.

With biotechnology today cloning are being done successfuly and it generate large quantities of pure and efficient human proteins, which are used to treat diseases like diabetes and hormonal disorders. In the future, a resource bank for rare human proteins or other molecules will be available. For example, technique like DNA sequences which are modified to correct a mutation or phenotypes , to increase the production of a specific protein, anitbiotics and biomolecues or to produce a new type of protein can be stored for longer period of time. This technique will be play a key role in gene therapy and curing of genetic disorders. Really the furture of biotechnology is very bright.

Taking consideration of the breadth and depth of advances underway in biotechnology, there is a strong potential and capacity for a reemergent, neosymbolist era. Similarly, fundamental drivers based on biotechnology will shape this new era of self-reconsideration and self dependant. The complete decoding of human genome with the help of biotechnology and indirectly of our physiology down to individual genes or nucleotides, proteins, and even individual thoughts and emotions may greatly impact our self-perception of life, health, aging ,disease, personality, and nature.

Today through biotechnology in agriculture we had changed the capacity of our planet earch in feeding the large popullation with agricultural quality and nutritive products. This capasity development and balancing will improve our relationship with ecology and the nature.There is a great progress in industrial manufacturing, materials science,medical field , disastor management and bioengineering which is only possible due to biotechnology and will deeply & positively impact both the nature and the survival capacity of humans. We the humans are the drivers of biotechnology and our ability to use biotechnology to create a better world for well being of mankind and also for all other living creatures like plants, animals of our planet and mother planet Earth will show a new way to evolution which will be towards infinity and well being of mankind ! Really the future of biotechnology is Great and is further coming up with flying colors for students ,researcher ,scientists ,professionals in this field & ultimately to the mankind !

The rest is here:
What is the future of biotechnology?

The Master's in Biotechnology Program is a Professional Science Master's Program, approved by the Council of Graduate Schools. This application focused graduate program is designed to train students in biotechnology. We are preparing the next generation of leaders in biotechnology.

This Section Contains

Our graduates are:

TOP

Biotechnology is a multidisciplinary endeavor that increasingly requires employees fluent in both science and business to enable the development of new technologies and products based on the unique applications of the cellular and molecular life sciences. The Master's Degree in Biotechnology at the California State University, Fresno offers students, who are fundamentally educated in various scientific disciplines, the opportunities to acquire the knowledge and skills required to comprehend and commercialize these emerging technologies and/or their products.

TOP

TOP

As a leading university in the Central Valley, California State University, Fresno will lead the way for new and innovative applications of biotechnology both in the state and throughout the nation.

TOP

Read more:
Biology: MS in Biotechnology - California State University ...

The ancient Egyptians used biotechnology to develop beer. Others used it to breed basset hounds, Boston terriers, and bull dogs. More recently, biotechnology has been used to design bleaches that battle the bacteria of major diseases.

Biotechnology is the manipulation of biology for some human end. Its the use of microorganisms or biological substances, such as enzymes, to solve problems, make useful products, and perform specific industrial or manufacturing processes. Biotechnology merges biological information with computer technology to advance research in nanotechnology, regenerative medicine, agriculture, and ecology. Applications of biotechnology include the production of pharmaceuticals, synthetic hormones, and bulk foodstuffs, as well as the bioconversion of organic waste and the use of genetically altered bacteria in the cleanup of oil spills.

The Biotechnology program at MCC provides you with a working knowledge of biotechnology by focusing on competency and technical expertise with state-of-the-art laboratory protocol and with critical consideration of current topics in biotechnology. Our courses prepare you for a career as a technical assistant in laboratories. The program includes practical experience through an internship.

The relatively new biotechnology field is booming. Because of this growth, graduates with the necessary biology and chemistry skills and practical hands-on training will be in demand for careers as technical assistants in places such as governmental laboratories, pharmaceutical firms, and bioengineering laboratories. Graduates qualify for these positions with their working knowledge of laboratory protocols, core competencies, and technical expertise.

Medical and Clinical Laboratory Technicians can become technologists if they get additional training and experience. They can also become sales representatives or product testers for lab equipment manufacturers.

Laboratory Technicians:

Before signing up for classes, youll want to meet with an academic advisor. Together, youll lay out an academic plan that suits you best. This step is essential to your academic success.

Advising for the Biotechnology program is available through the Life Science department. They will help you determine the exact courses you need to get the education youre looking for.

For more information about our graduation rates, the median debt of students who completed the program, and other important information, please review the links below:

Read more:
Biotechnology | Programs & Degrees | Mesa Community College

ARE YOU READY FOR A JOB IN BIOTECHNOLOGY? Associate in Applied Science (AAS) Certificate of Specialization (CS)

Hands-on lab experience: Earn a new degree, enhance your current degree, or upgrade your professional skills.

Internship opportunities: Working for cutting-edge biotechnology companies.

A working professional? The entire program is available in evening classes over the course of two years.

State-of-the-art facilities that surpass most four-year universities:

Two degree options to choose from: Associate in Applied Science:

Certificate of Specialization:

Hands-on: Students practice lab techniques on millions of dollars worth of equipment covering a variety of bioscience niches the same equipment used by researchers at BRDG Park.

Workplace learning: Students benefit from the opportunity to gain real-world experience, and often want to extend beyond the 150-hour minimum per semester. Workplace learning is a requirement in the AAS program, but is also available to students pursuing a certificate. Youll be placed with a company based upon your research interests and current industry needs. On many occasions the companies requesting interns are interested in finding permanent employees, and internships often lead to full-time jobs.

Biotechnologists utilize cellular and molecular processes to develop technologies and products that help improve our lives and the health of our planet. If you enjoy biology, this program adds a technological aspect to your studies, preparing you for a job that will heal, fuel or feed the world:

Youll learn how to:

Faculty: Our instructors worked for industry giants like Monsanto and Sigma-Aldrich, and bring that experience to the classroom. Youll learn from seasoned professionals who offer one-on-one coaching, extended office hours, and opportunities for extra lab practice.

Stackable: If youve earned your LSLA certificate of specialization youve also earned six credit hours that will apply towards your AAS degree in Biotechnology.

Professional Networking: The BRDG Park bio-research incubator houses more than a dozen exciting start-up companies top innovators in the field and students regularly interact with industry leaders. In addition, as part of the technical skills assessment, students showcase their ability by presenting the findings of a laboratory experiment they performed in one of their courses and defending their skills to a panel of industry professionals.

More than one million students have attended STLCC. Its the largest institute of higher education in the region, and the second largest in Missouri.

To find out if STLCC is right for you, we invite you to visit. You can meet with one of our faculty members, tour the campus, and get answers to any questions you might have.CLICK HERE

Companies that have hired STLCC grads:

Monsanto Covidien Sigma-Aldrich

MOgene LC Benson Hill Biosystems Arvegenix

NewLeaf Symbiotics Gallus BioPharmaceuticals

STLCC Career and Employment Services (CES):On each campus CES offices provide services and resources to assist students and alumni in finding full-time or part-time, on-campus or off-campus, internship or co-op, permanent, seasonal or temporary employment. CES also assists employers who are looking for qualified applicants.Click Here

Job Resources

STLCC provides a top quality education at a much more affordable cost than other institutions.

Jennifer Hill, M.S. Program Coordinator Phone: 314-513-4953 Email:jhill330@stlcc.edu

Please note: Fundamentals of Chemistry I or high school chemistry with a grade of A or B within the past three years is required for entry into this program.

Credits transfer: Students who have completed the AAS also qualify for transfer to the following programs:

We invite you to meet with an STLCC advisor for one-on-one help in planning your career pathway in this growing industry. CLICK HERE

Related Programs Life Science Laboratory Assistant

STLCCs Biotechnology Advisory Committeebrings together top industry professionals. Members serve for two-year renewable terms, and STLCCS faculty works hand-in-hand with this elite group to evaluate and update our curriculum, stay up-to-date on the latest innovations, and promote networking.

Resources STEM Scholarship The St. Louis STEM Scholars (S3) Academy of St. Louis Community College-Florissant Valley (STLCC-FV) provides financial and academic support for students in challenging STEM disciplines. The purpose is to increase the number of students completing associate degrees, matriculating to four-year universities, and entering the STEM workforce.

The STLCC-FV Biology and Biotechnology Users Site Provides description of equipment, standard operating procedures, and protocols for a variety of instrumentation used in the courses at FV. Additional training and educational aids are provided for interfaces to other key applications.

Bio-linkwas created to improve and expand educational programs that prepare skilled technicians to work in high-tech fields.

TheMissouri Biotechnology Associationis an organization composed of individuals from industry, education and the private sector who are interested in the growing field of life sciences and are committed to helping educate the general public as to the importance of the scientific discoveries being made.

Location

Biotechnology classes are offered at our BRDG Park site. Students may take general education classes toward this degree at any of our four campuses, our five education centers, and online.

See the rest here:
Biotechnology | Home

G R O U P S T A T S

When it comes to advanced scientific degrees, we field the largest biotechnology group in New England 36 members, over 80% of whom have PhDs or MDs. We aggressively recruit people who develop advanced technology, and who speak the language of inventors and scientists, quickly grasping complex biotechnology matters.

Our clients include both large and emerging biotech companies such as Biogen, Dyax Corporation, and Lantheus Medical Imaging, privately financed startup companies,and prestigious academic and research institutions, including MIT, Dana Farber Cancer Institute, and Harvard Medical School. We understand the different needs of each client and bring practical solutions to the table.

Our expertise is broadand deep, covering areas from antibodies to transgenic technologiesand everything inbetween. We also call on members of our other practice groups includingChemical & Materials Technologies and Pharmaceuticalwhen their specialized expertise will benefit a clients project. In addition, our teams routinely include support from our paralegal group and our International Filing Department to contain costs and deliver value.

Our group's services include: IP strategic planning; patent portfolio development, acquisition, and enforcement; studies on patentability, infringement, and validity; IP audits and due diligence; licensing and technology transfer; defending and challenging patent validity, including post-grant proceedings; and freedom to operate and competitor analyses.

Representative clients:

For older news items, please go to News & Events.

Laura Vogel presents at ACI Conference

Wolf Greenfield and Client Cold Spring Harbor Laboratory Prevail in 4 IPRs

A.J. Tibbetts and Ed Walsh Present at BBA's 16th Annual Intellectual Property Year in Review

Wolf Greenfield Welcomes Counsel Laura Vogel

Wolf Greenfield and Client BTG Reach Favorable Outcome in IPR for CroFab Rattlesnake Antivenom Patent

LMG Life Sciences Recognizes Wolf Greenfield

Wolf Greenfield Welcomes Shareholder Jeffrey Hsi, Expert in Technology Commercialization

Wolf Greenfield Recognized in 2016 "Best Law Firms" Rankings

23 Wolf Greenfield Attorneys Named to 2015 Massachusetts Super Lawyers List

24 Wolf Greenfield Lawyers Named to 2015 Massachusetts Rising Stars List

Oona Johnstone interviewed by ASHG for Featured Chat Fridays

Managing IP Magazine Recognizes Wolf Greenfield

Favorable Outcome for BTG in Snake Antivenom ITC Investigation

Chelsea Loughran talks about CRISPR in Xconomy

20 Wolf Greenfield Lawyers Named to 2014 Massachusetts Rising Stars List

22 Wolf Greenfield Attorneys Named to 2014 Massachusetts Super Lawyers List

Pat Granahan comments on the battle to own CRISPR

Pat Granahan and Chelsea Loughran quoted on CRISPR-Cas in Nature Biotechnology

Patrick Waller interviewed by Radio Entrepreneurs

GenomeWeb quotes Chelsea Loughran on IP landscape surrounding CRISPR-Cas9

Wolf Greenfield Recognized by Managing IP Magazine

Chelsea Loughran quoted in The Scientist on first awarded CRISPR-Cas9 patent

Chelsea Loughran quoted in MIT Tech Review on first awarded patent for engineered CRISPR-Cas9 system

Doug Wolf featured as the Entrepreneur.com expert for the month of March

G R O U P S T A T S

When it comes to advanced scientific degrees, we field the largest biotechnology group in New England 36 members, over 80% of whom have PhDs or MDs. We aggressively recruit people who develop advanced technology, and who speak the language of inventors and scientists, quickly grasping complex biotechnology matters.

Our clients include both large and emerging biotech companies such as Biogen, Dyax Corporation, and Lantheus Medical Imaging, privately financed startup companies,and prestigious academic and research institutions, including MIT, Dana Farber Cancer Institute, and Harvard Medical School. We understand the different needs of each client and bring practical solutions to the table.

Our expertise is broadand deep, covering areas from antibodies to transgenic technologiesand everything inbetween. We also call on members of our other practice groups includingChemical & Materials Technologies and Pharmaceuticalwhen their specialized expertise will benefit a clients project. In addition, our teams routinely include support from our paralegal group and our International Filing Department to contain costs and deliver value.

Our group's services include: IP strategic planning; patent portfolio development, acquisition, and enforcement; studies on patentability, infringement, and validity; IP audits and due diligence; licensing and technology transfer; defending and challenging patent validity, including post-grant proceedings; and freedom to operate and competitor analyses.

Representative clients:

For older news items, please go to News & Events.

Laura Vogel presents at ACI Conference

Wolf Greenfield and Client Cold Spring Harbor Laboratory Prevail in 4 IPRs

A.J. Tibbetts and Ed Walsh Present at BBA's 16th Annual Intellectual Property Year in Review

Wolf Greenfield Welcomes Counsel Laura Vogel

Wolf Greenfield and Client BTG Reach Favorable Outcome in IPR for CroFab Rattlesnake Antivenom Patent

LMG Life Sciences Recognizes Wolf Greenfield

Wolf Greenfield Welcomes Shareholder Jeffrey Hsi, Expert in Technology Commercialization

Wolf Greenfield Recognized in 2016 "Best Law Firms" Rankings

23 Wolf Greenfield Attorneys Named to 2015 Massachusetts Super Lawyers List

24 Wolf Greenfield Lawyers Named to 2015 Massachusetts Rising Stars List

Oona Johnstone interviewed by ASHG for Featured Chat Fridays

Managing IP Magazine Recognizes Wolf Greenfield

Favorable Outcome for BTG in Snake Antivenom ITC Investigation

Chelsea Loughran talks about CRISPR in Xconomy

20 Wolf Greenfield Lawyers Named to 2014 Massachusetts Rising Stars List

22 Wolf Greenfield Attorneys Named to 2014 Massachusetts Super Lawyers List

Pat Granahan comments on the battle to own CRISPR

Pat Granahan and Chelsea Loughran quoted on CRISPR-Cas in Nature Biotechnology

Patrick Waller interviewed by Radio Entrepreneurs

GenomeWeb quotes Chelsea Loughran on IP landscape surrounding CRISPR-Cas9

Wolf Greenfield Recognized by Managing IP Magazine

Chelsea Loughran quoted in The Scientist on first awarded CRISPR-Cas9 patent

Chelsea Loughran quoted in MIT Tech Review on first awarded patent for engineered CRISPR-Cas9 system

Doug Wolf featured as the Entrepreneur.com expert for the month of March

Some areas of expertise

Read more:
Biotechnology | Wolf Greenfield

- Industry Medical Service, is a company with capital of 20,000,000.00 DA, dedicated to the customer, as engineering teams, commercial, administrative and put at your service: competence, dynamism and creativity, Industrial Medical Service make of this development and deploys a technical and commercial potential to meet market needs in laboratory equipment and specific applications in the field of biology, basic research in molecular chemistry, immunology and biotechnology.

- Through its innovation and expertise, IMS, is positioned as an essential partner in the laboratory, close and listening to its customers IMS,aims for to promote harmonious development of material science and medicine in Algeria; in commercializing reliable equipment and maintaining controls, monitoring the after sales services to maintain a quality of service reputation.

- The technical equipment of IMS, with its ability to meet user needs in: research, development, installation, technical support, training, customer service, maintenance and spare part supply, allow taking into account the needs the most diverse and more specific in order to fully meet expectation while maintaining quality services.

- With this experience IMShas increased its contacts to optimize all uses in the fields of laboratory, biology, hospitals, pharmaceuticals, chemicals, petrochemicals, food processing, industry, bio henology and research. IMShas major operations as a partnership stake in cooperation with domestic and foreign firms.

Read more from the original source:
IMS ALGERIE | Industrie Mdical Service

So&x)% rPnDl@} ]*'`sB 6&!5S jyQw@ %>V8f7mq{h L)EK2@Eq(&d ;!#(!'o~IqPCUMKpUSnzE`@YM>W[^p0VHbn My5W|(XtwxXS2AKY,I/uBCZZ%ym=B1OCBpd-y92RQOb4RM4 y0}@~}9g%l!FYLmw^6J}*dRc5EB@:YE?"TCQ]Wb,?YG5F(oh@a {[ Z0=^m_!@s1o @ IP)Dk2Jdy5[yr86,Z(9}wb$!-n *zVw|hiaw~Z Q|5|rh ]}Fmn+eH #.$8SSb=MX)v?s[^WpP"G.:Zv^@!8P9z)`T9z:JBDI[GDwGI.p[@L+aBjN6pr*R

..Wv kWPSq[j{]:l2 )C*eHiijlP-QpO}:29PMcC-'3(%gDjpXAacTVSg|.WF4!x]@f`6Ru R+Gh! qd|+;_G;MiX&^luG|jA%-9a;DxZ^6X@CR+v}GZ+Vi{Jm1:{wm)Kx6K/emNI:ak E)BR~kV,RkPr8hb29(&5{ 31v}gmm.FIIRA}CVC:P iBiAQ&jOHA~#PO%[x}:k)P9#DK ~RdNAE_B9AESyo.?7w>b~|:gFvo77;Mfz}}52|rFNZ?I(r)`~>3$gm[ve'IWkAU%4o&{7.FxB$hCG;Tmb>.{7>sOHYc7< CZGniy@R_IA*i]F-!E pYS8{SV7{ xtm}d)bQii~} o/PZiW6GWsJ:Gn)Tcz%SCUQGJ4gjFz}_sA4.bZVPW0'j(E2??xn}jvR)TE"~Ni>/fL|va14WLRCnw5@*i_WC%(JZs(E=6u*)go=pSt.I`FBGIa]ua"_}&fe6Y?N^5YO5%rF65vCUxtNUx=kVkTx#wzu46Dq9)B ,(`;Gwfe{eC9|2zBx>C1;i39W+!eb,AJgP8rp$m"9)z{^;nQv.]$E@wyc a%o3AZJ^U?|7}0;l]];3WOm:muNMuxir;;^SUP5%:cAp#_wxLLjg7+2mcwH Tw5|v!yzF2}sByk _Do8;&Y}%-ftGD>4w&(!^tAa[~}j6{:2;4" A6~l5 s5OLDHEyEK A{whI4 !5g9X-QkrXyN(7*U!8]7q`gy68 `nv;>| Wq%3oct%S|+Y2w(Dj*xw6nLzi^o9SaHf+ojv+B*Q_^zt0ial5([);/ahM7CJJ| {<{e%H]QK0'QsCikVROvUb=;nbSUo8)yx>W|P3=kkNq8UNKB2*hiQY:1{ 2Nun$a}=ng'1n;;` P endstream endobj 5903 0 obj <>stream hl 0D%_Bz*MB1S3;+ ##`+eQQOkIV9)OO DL='Xz hFJR^`JO*Vh7v5wX CK9H dIChwn-q;lD5kP+MN endstream endobj 5904 0 obj <>stream h$ 0D.7iMP RtqjhIS,rXj!b:KOrE$b-;' 0pyzV!j/z'}7`k:TU!j8^4w`1g-S,yD endstream endobj 5905 0 obj <>stream h[]o]+|lJq.YFEE`NTrwVZ PG|Y.wgR(^K-N Am|!IFsX]C/8Hp#w" Z% iu k[Phw)Z2u2#`@5+dA[R"|CN8[sgB6q" z"+b@y R{#,T@Kd`Q4z=R ptVhI^`,TZ`S+G%{ Z=a4<$2.Wx7=+2hXeP ZaN3Gkx# ;{]Wx=W^[u>HBq+ioJ#V_KB8[Rx`+pDV?%p D,Pc8.jLr'h#Pi$'ib$!t4c8AGt&*p1@)&94 I;8d4 OS<-Wwk@JJ/# tb:N'(.wo. %!.t)_^QI5rj~{;3>bH4ZCCJlXMcuGCcLA!1b[{xSJ*CVeu{XCL{ D{^]#|cB1y@' l:O&&f]5#HWwYz~N4^lrF$27ErxlrFd"S%iR&x =NlAD{GS ]aE(j }4U:Z&{iH0xpY)c&s<:)ZT n6e{8 $*HYj>j'5od0!2 |)Zm 6l>OrT'>A`YbV}`@XFwke[ An"JajEZ!v VAH-G"R-fa5R&-VSz4Cybu 8=lD{L%L-2 &)I:W:"#bq;% Mh-XPRVhlL;5CcWzV.ZUxT+GcBB5 "eWEWo e"paR&uCLNr"vj6A'hz]WG_bk"8(R+`e/096qqE6n4u < *acuol"w~y9C)Z2Qxlp5*2-b0vfLp|x7 8&(-t+@dzbd2l}}BW~GOQbx*DhDvD]kd1$?b |62N'wygCtB!^; !*DFr~=DdPuTH56,f .+7;d&V+DJDB_ 4ECST"*)AaYrx!:0m1kT*8Jz7aT?}DJum-%6@|CF K;4lnceY4za7wl.<8hi444=/i!1{T^o&B}n$7[ fY>N/VKtv,rn^Yq)> endstream endobj 5906 0 obj <>stream hTj0~?mN[CP,NKc,0H6h4q2EZe"tjQ>[yU}KK"P?>'n4}>c E"!(f`t4F>8f :cAkwZV!xFduYz2F^onwC^p5?{'Z3^5M|R*1~`-$e);Ee?0)x8-|S ,CXCfR `C>gSq endstream endobj 5907 0 obj <>stream hJ1_%O6M?x10Vd;:;/"qcH@1dp", 9$0l6|uqA]uNHZ.=.=IDo:t|%u;W,in 45`h0K L~K:u4lOJ;" k`QwLtFWS^No/w endstream endobj 5908 0 obj <>stream hJ1WLHP{+=5lzA=$Hd=F?UZL.!zNc'qis!7m$WZc2P.W`]z`gwpoQEnjHOk*8 endstream endobj 5909 0 obj <>stream h[o07M~JkI-$( w L< ;Aa #BG8w1DHdDjN1D,%,&KEh5M63f#'F&TKu-9uOYz-,0:2Xs0Ip_aqQR5T-UJxG$E!*8U"Ur*zS~j+P2:;CvPZN:4|:Wn<&CU6rzYV*w2*`: %mRCP@ PA 5la]e dpe,m$}~7}aV7p$yi"m-*37aY7T)SWck;:CuNT8<3~vrTYHyRYdPOs/nbvg` endstream endobj 5910 0 obj <>stream hMj02,A0$.m].iE(%u}GvBI Ho4#b"W>vE(@3A3;g!Y]Uqcp:t'XqV ln{o"s.k(/a~:osecY^@`C9`aRVHB(vM`dMU0Q<}CnnqCZm0_o2OB_N|?-$ endstream endobj 5911 0 obj <>stream hiS72?e>&}TRC0=`klw=7L IOWKKZXO mzb`aF {{L _dQ+zILhc3P=-0{Nr3cX{YH"t[o12EIQ8}:I W' )%vP|iNAJ4/z$00t+xM1$$JL*LjJh 'I &Ks5U$t)%!=$a$kp$~- p7%~$aS J2Bd ID7$8Bk%0)1+8f$fn6"xp+% i`FaYcFs>4/?}0_?t?JcXl w pruyqw5?nt_,HSwjCf/I<< !||MzJQLfUB7A#_B9G "`E!AZ@/XbiA`m9hXw1b:6KepLA61${y==4;fC(Mn_'zn8{nwPcl}m~<{$"/{)B#cj^&M4Dv"Sjt7?_WQKTl6ih7r7VJL2st&PS2|d!X%rxvt1E6CF/Z{'Fi1V n A$s>@,,KmVlY3ELz]L {9ag+>NN (p!ve5ll3GjX@bryq.^M7)-:Ba !Vz@pr<9"+,r+y _!3y=G3 jlqP-CXVSA:Q|"xIlID(q0"+96u,LqMU75ETi-RukCzpQCjG|X"!,B0p9%z3<<.QDr.uEMPf#yPUlc9F"c~{05CF%:,}u C4&(5Ub4pV9kA o(@+"#q`7.H%k>0ih!5M8hmlu2?>z 1RQ,$Ck OAIpETBD)}-;&1.|C&VsM-"`L"[0q>48]<(h$D^V!N7 C0:M,YPF3$ $]C1`]j &k3b;RxE7^q^.Ti^[H#O(qyB/ms+D)d)zNWs>?/8*)^xjXzykioVC{XtYG(tWt6bEQ /s:_pn+ddjucDlo^(Of^igB~XO_o3m2qE^`*MU7x%bPiy:X0h~Sp72o&c|Yq3_l K# v->/=k6/[~p } m0fic=Xw-zcqnfN(lcu2UGWb1^<4Y-]lk%4o>.H$%X^ HH- "A$5La$iz|Ak >rtn#f/$MgoXX WwR6gRwg[a+8:r8!(1d 2Vup&z}@Z_&]vgfHoK'hBOlY V2hS#5.R.z!Emp)]MH "HDi27MuBKsb|ZSP!, ^ ZAn 3Pb?z/]Aw8.vsl=w~? hl_]|[X{:urV/!~/ju:x6Qml2qoFPj?5ofCu1799=({xw7M*eT6:oKZp7-5.ZH?To-/.O}*HTwkYDZB )k3IqEa.F6GGfPnaKs0{]x=J+w}MmyZc2IMWw)=,m9KgtI/0N;lS}Ef/?3w_;mebzvB7-B78]{IKFRcVr^<:]eQ#]8uU.:=::;__B,5u-b lad4cyFn7,$%iZz%&mf AH' 9qjc4@OrwHiSgxdWmtr!D>9a|BqMww*&<>stream hZi+10x3b$#Vx(o"bZ#X"5Xr2eUf*4<xuy~}wYwwno?]f}s~;fx?^~Z}}|Y^ZW6whtm|Z1g?X_e_Z;8S<=M%7"{ro.oKapqY2D_*s ) mYzKY^z0_Z9li)v"LO=/=]C LY*E}[^4v] 9:;-emn2z-Csd4_}H9v |MR2TU(%!HiEW+OQv, +GWkBEKIEE!yKZ5g{6bi/^KZ!"C?Ii(Q'LVwjDsJV#,6o&7E>d&WJ*4e,+J|Tn)2xx4`slO]Sc^aoBM$C)RTe';U$Sy]>9}X.|"8(HQUMT)KU`/)9[]p+FM1y hb3<6R^CtQ*yaB,YxIcD,; z h-2lJPXE 9oT ^{il1*i5"Uhg/x g+|gi&5e%%3t,ofCBWg/I 2M`V19UP a-qx;yS:!246}vU n;~x>tgC&Tl_O'y??%I~:4{=4/QA{7:`;#B|i@Gr{6-La}i3zm;}o)I%f+wjOoj*w886=T<cWE; lng -?s5Uyx5o5;OWv/&MXit?pr~_)3lJkTG{CG=O(2Zo1G<[.7Tfn2qlo*3S/^XnpZo+,t?n0 T}fC`-yZ (xCVu)^s<^YcW(|^o>xs_/:/o?^o2$(U0f/)O3KJ==<=3j=3h}-zC jw{=z %YSCUB8BzC$e&y6Rg1o0&bH^G(g2ma=+=dZvGt}C=kSgKVj&GY{3Yn%k8DCq xs7W@TyI,0*en*4sH{Ucn.J+|Q,w_@#{){TKvun!o{s.)LOV_CA>[}TZpCt'h?0zc endstream endobj 5913 0 obj <>stream h[k0y %7Rn#sT,A'Y.::3eU2,8n B":$4hmBh&Wu~FX&-i(Jo>6LH$)O q`B&1)5}Vaz!YA(rHq @FTZJ#mt+ Ib~8p{axp$AJi|7rs ^S^!V| 'j1w&|~Tn|4%?tv>6,?a_.r kpFHk|YoH4ydD*[O endstream endobj 5914 0 obj <>stream hdQk0J1nTB8 3CCw5#MJaKsb$D1[(1)!*,+v9B!Qd3 ;%,`glwA/d9Tv89H]tTy 9 Q4y= Yt 6B yQ JVzk68$36Ixa5;W{E+u=~n)$NVaB?]uY,0s[sJ2I~ endstream endobj 5915 0 obj <>stream hMk@J]WB4PZCAS{**DtDzP0Dc(H*:8WWQ0xI'U{ID1 DD$ Lg~iOo?"RK8hn4H#%Hck>stream hdn0De"EJKCU>Trp*jUbd}wz|3h j ==MVU1Oa>k|CES95f4'NfhUY9XG,lUX-Z7@,6&tVsI>z`Pe`v~ .pZ2Qd=h~G3,Y} endstream endobj 5917 0 obj <>stream h2164P0Pw/+Q0L)6176 )0 a cAf0s#V? (hXF? (Zlg`OA endstream endobj 5918 0 obj <>stream hXjG|}LC,0AtgzvzWND?t{]U=G!M!LrY LY8y/("M>@Oe&`_d*NIV&eU6d&eb.M!N?j(dW]lv/zsdzzuv}quzsumufo/^l3[Kwovsr})[uw]6e}bl~L@|rr|:|[7rWdQ4NLF'b>>t!1B4bd ORI#fZN)?9S~3=GEf^,Qst:k9yV*82b%gWb}1`c1!52A7fahV<%=,,[]1o8 |n#;:5{EEnsN""Q")j8hNRsJ)j8TRJ+z2)z^y{4Wpv/N D;aNf0vFYI &*d#;W#W#H{:F1("_ H}p+ 'NM:t76!t2$NlL:I'#t2I'#1cb#Wi11+&lHsEsyj<5>#g0|Fg4|Fg8'3l|FQgQ 3?B0>)@!Sp'EgNXNbQaRA! G(J~$PJ4@MT @*Fxh'.&L>|O>>OO={zD>}]WyDq endstream endobj 5919 0 obj <>stream hZmo7+3VoPKsb6^$^$Gf58DR$x!_/7 F"P -dmB;&@Lxa L`" RXk{+3w1g3gc3 gA 9#ssp"2Ed@J9QI` !SZ(2H"G@D6e #)M!AL@ eXB22g ed ea ec e@d e8M02` exPg exPF` eDDGBC d"58 4:(jH9a%Y2hQZ @+#Yp0 ;-:?N&"E^nV{5[$QhY{tc)`$:`(, Q,Me^HvzIGaH&)@1Iapka gF j6EejpZ UjA

<)tzOnRJ%C.o"(?9$^cogOSkq?>I<1#A.7q78 ASvWt2pET("]d.,c[P49y7-_Y_u7=:Jl=mkn=x }70PLM;)qh&Ju[>TvhWFF-lJ85 l=rg|yVdnQ~CW]j43?3dKK;bG}wsW{#JFZK1l]?}v_n/.mywug'o]I&--mTCTNAY1n#ig5f8oBQ?uG5 .i}O?6:3E!{a#Zlz_ +n`Wo-;?/dKq4Op*zh]I^g=p+jzpIGMM~|nJ9rsv5Uo'O#y endstream endobj 5920 0 obj <>stream h2212V0PtvvJ,NMQ04X endstream endobj 5921 0 obj <>stream hj0_E-3F%J '/vmT&Rt~}0`!#p9CIN;# ywM$ E.fAcLm/*Z&;.ZlZHW01yUMHWc}/;L,x9Otlome}G(x(Gi{oY*];h2qMViID{wd^fpk8YPR4#!Re!~o K)+"~0&!L;Lm2 VUuJOPaQ X$A@`D.|p.:o`{)WHHI[>stream h2214Q0P0214S05 f`BL[*Xh#K0m`hf))ekxdTjgUj8'jm Eb[eD. endstream endobj 5923 0 obj <>stream hWn[7B|? hE&v~ VQ;g(JjgB8pfqOjznif/~[?W?^^=?mw>LiG3?o7I+Xb&y_m!lK1PSiJ11Bp_pm<9sXOksS6zL!D?k=y`Rn}>2s~<=M:!^Lfs{}{~k:3Iz?_ptc(=_varq_2D&^*g|$n~[h_d^?/uOatNKHL^SuHpm>3;UW3TDE?G~-f?$t*9mca_[ :b`|K6.jWbw?PTAaecXLvv(j):Rh!0 7GW6Ybq"F@I#Qe#CtKTo^'G(Y';zu0:DgjJn#,h&[4>dv3M[h^W$O#,2[)j5L=HeG :;Hayo"@9WevP^P+5i/kGer,Id*8o/P=7*Xy 3v l|;zB=|Py^~a5VEMu ;* )a9%tcPJ6w?`P }eO $*3OiV9vx]J-jS!LnR/ms;4>P lV9D"7=` TXl'@X_ kg$g3~dx=G3zs7w6[9W#m{f{nsc=pv{{)5wQ~y/mG2%%gshq#/Q&35YF79K| v,*RNW`J endstream endobj 5924 0 obj <>stream h,Ak@+EfLb& V+ wD ~~xOqr_I2L_FDk a!%=KbwEQ^?]vQ endstream endobj 5925 0 obj <>stream hWkGW`Hb!&DNzP#,c]iw~;w]>1[kmZG7? O?pbXo77g.~Hg,_8o/~]7Z)BYy|02<`=^/2Fj|:qF5^eF;`=D?3/K r C Zgx~iY/LuZ.hD/gm3@c=d||&Gv?%qkcvP>!Cyla=u~2bhro"t$kr+q.?'qVIKZ1%nSQ H|y5}r)9TZj@pf9-9(Qv7G_5wkml}mwJPrJL#kVV%b*V6%Ahe4y$$%14"tU`H><5y6 G9TSX`q%MTQFsN2RbW*_X&WtPdg: .O)('Lt6i;+w^7u/Tb|]^OMvS&$U1 -1E!D`+k=IC??<9&uW~ rX+g_EO-xt'q$c]}Dg: +sdSX#HSaRh29OzA av`n%]:aj_ `o*-l3!{@{E|nHeX>*U)CStLc1QFVB9?M<}I7~u{/|,v<{Jl^XOcOm}wKRnuV_2C^NOrpC7R|QX 4A?i[RAzbUl'{syFkz>~ {mopt/Ak{tPInDvA=/L_K+ endstream endobj 5926 0 obj <>stream h&qF_f7 $J$E06HiP>ujFo%vSd?[mqmoqk~Zm/>yo/|=>o6{xs _k{h~G/z>Y4{?xl?i$olX3i ZBlq`g_|x>}O_k}MDOi/E$s^x&{r?|=Ck+"m{U"ZO10{D5^?/o 3WnD8^G{=o_acEH1$a'cDZi6Me^g>C3}t0hCs}.!LZwiQmG[jx8Qh@Xm,bCrDq6lw~,BEtxXkb]{w&tGcScp?jLsZljFX=xxX1tlGcV4cs*:k%tc}g=WXZgjTKgLL?gpZ]U&~XtxhuFcBc-+tJ?;LX@gd}=5Vg<*4e q2z84^v.bN!f-aSc Fwg@1)6Nws,[d#z:JOtA&U.12X1{3c1&ktlH:]o$^$Ij8OI/H:Vz&Z$A9KrH3AsSN'3y4X=GBS#s[k*zOdj8jM;!D+Jnt eh;2n56Ut);[2-&o:5|M2 L:/Lz_#bzeT2*OD:.w310XD.n:Fp}qe xc`>gLbu:noHus85}X1dnJ6BN"X!lSJHBX!lWK+%X!lWJ :vu aRBbC-1PX!PJ_`,SJ_*BR VJ ZJX!+%pa^Yl aRb2X!,)!T(%f9X!TJl%v*%N@X.V aZxM)1u aRbRbs=VJ,RbX!l^6^|6^;6^9+JidX!LaR0nX1.w)URU({)URUJ0%rT@TT005()UYX,NKQDcysh3Ig$&M4?Z[?Gyo,ls{ky&_ endstream endobj 5927 0 obj <>stream hOk@Jvwv/m5KC6 tHb56PJ1cJO3JS@St`@zX(6,D[V{^[@1 Z~H8G%>stream hUM@+}F%IiSvRH6=WcbBy[M%7MFw`vIXIJevW28ac G@ t^V,tD OxA:KOfWg@3H|? +o~=:3n@0S~ ")6LS!?z_O[OeuP1 4J4D Bl!hV{Z*{*)VBJ!hGx3]z[utP2`tyq(NJ%aJ>mA8$02 Q59/+ )0%EJ-bQX)*?a>>stream hUMk1+2!idz0!C}G^B{XI4z#Au[ +=dzj!P1@ QR*eHH4;Dg8U =sTye&q. . wp4@g=wr4r2|l.}OA0=_'6&`QpnDk0xaakr|:o6VGbhYLhKudR4[d~U0XJjXGPPfl@B$)@ RP"ZR`YRuxCo^@J xyj`jud_lU7Ii.}Et%!ZPUly-b+ymi>Ln5;9w|Fz){cY37L('M Sc&WGL'w endstream endobj 5930 0 obj <>stream hRj0HCz0!Cm9!4fVeY!1g S`@@Hea"1gWf-kvg|gkxzO;vEg`_,HbG1gv9<$}R8la;_'u$ 0%.i, r ::"rYGn85b*@ gq?.JLG2reP6b/# endstream endobj 5931 0 obj <>stream hj[1_O#dC)E;e4mOr6P3"9r%YJ,j8ktbFKbb2JrLVNd*#{skaiB%,aD*}EKd++b+Xa114Qjxib)tv]/jy>*~l{UiR'ps]>n,anwU (UT- 3e@-= Ze@h>SJA-As/rTPQoSZ_R14>9WdZZD%dnyGl fPUa3T?H*HK hQ&J3>stream hj0_EO K%[P e^n4d(}(_8'|$1fsDIr&fsBBr36p%nk kFkq?`Ap*hq HJAkD ?w!opqMTT$OT+j=iS2FlQQ=y2f]+,hf{[a]R28 E'&e%.ZU-X*jQnW}-]+UB9+Ty8^VWW_wt:J7/ endstream endobj 5933 0 obj <>stream hRMK1+L2$VaC{(BWz;xPB7c1Oe ]&O@kPlf5W-|b8}l6eFA}+_F$F!+Ls$|>stream h[io9+A+0 nAX`~MudwdGV-R&!L ,FpMF(pbXQQ&QR1k444-HK$GMP8HK0D:A)N)5ph%C8)@Xj)HK$gb%Fr'eCDa`aR$pcDh## 'S&(A H#OQ^iCEED$HK*%Jpv9kV#G $ib!b?8:(T8l$F@p^/4LH8rEEr0Q|&sYO ZEC]utDP=//P` U wDe%EM(H&7:RJ.a,?hN_g'ek^}?^.l0],+`|y-A1qhz1B3LW lafa#4r<^k5+Y*7;k:fM/ufSk1YZ?1+G{_/.t]="DXj v`1c H 0 |nCjx~_^7{2|~M'iY?gW*4:~?>&IKGtA nj:?m=}y~,NXRx,J:5~|{?p60m"Dq1yVce>},+i}u(:L}L20Y7~r5}F{tsBdxlwvzekY%>nfq|spp;.1?vok-Ksr7j"Bs5Y1e%.Oc(iVwm3~b4}mW4rCwe_},-*v=}>uIc4WzfqQ+!} Q;u wy_2Y]z5s1IU{mq0nU=^]__Bs4z{]:?C!tueq qtKtt&,c&XI;a@X6Qp>QV?`F|]ON?%es&:2g7aYMDO F9<]@7+>P2MKbk?KNWp'o@O^a?=>>x 8-y6q ap4C8KV-_f'p061S*H8#1uClwi_6$ 5[h``%O7b0FA5M'Z Cn!#8c?;ZS07Bq4{`ob VA)xw1d;e*!< p1y_Xt}"=+&|V$*/ -3rW B,W[k=> ]Xgx !_5ub?pY4NSZN#AT5jccF2,<>1"z ]'o;c"2(z1h5cVirsS-sC+?r~=AKN8~KcY$="YIEGN1]Lgdqo=$WS*;sfh#IeoEl8uxg: /u!.x&/dT.S@KK3aLU l*iFAT3|>/ ~YP,dveWUJ^< x%pw?XHe}JTs,guA&clZ^AYmaQY)*&h| i[}?z{BS>OyXlM-p.1.r*04%P{Ikt&1IX;N5

See the original post:
Journal of Advanced Sciences Applied Engineering